MAR Neurology, Neurosurgery & Psychology (2023) 7:2
Review Article

Central Nervous System (CNS) metastases from Small Cell Lung Cancer (SCLC)

Melisa Hunis MD[1], Adrian Hunis MD *[2]

1,2. School of Medicine, Universidad de Buenos Aires, Buenos Aires, Argentina.

[*]**Correspondence to:** Adrian Hunis, School of Medicine, Universidad de Buenos Aires, Buenos Aires, Argentina.

Received: 28 July 2023

Published: 01 August 2023

Abstract

Brain metastases caused by small cell lung cancer (SCLC). This typically involves various treatment approaches, such as surgery, radiation therapy, and targeted therapies, aimed at controlling the spread of cancer to the brain. The effectiveness of the management strategies may depend on the stage and extent of the brain metastases, as well as the overall health condition of the patient. Further research and advancements in medical science may continue to improve the treatment options for this condition.

Introduction

Central Nervous System (CNS) metastases from Small Cell Lung Cancer (SCLC) represent a significant clinical challenge in the management of this aggressive disease. SCLC is a type of lung cancer known for its rapid growth, early dissemination, and propensity to metastasize to distant sites, including the brain. The occurrence of CNS metastases in SCLC patients has been well-documented, and it carries a significant impact on patient prognosis and quality of life.

Frequency: CNS metastases are a relatively common complication of SCLC. Studies have shown that approximately 10% to 15% of patients with SCLC will develop brain metastases during the course of their disease. The incidence may vary depending on the stage of the primary tumor, with higher rates observed in advanced stages.(1)

Age and Sex: The development of CNS metastases in SCLC patients is not limited to a specific age group or sex. It can occur in both males and females across a wide range of ages. However, some studies have suggested a slightly higher incidence in male patients.

Symptomatology: The clinical presentation of CNS metastases in SCLC patients can be diverse and may depend on the size and location of the brain lesions. Common symptoms include headaches, seizures, focal neurological deficits, changes in mental status, and visual disturbances. The symptoms can significantly impact the patient's daily life and necessitate prompt evaluation and management.

The management of CNS metastases in SCLC involves a multidisciplinary approach, including radiation therapy, surgical resection (in selected cases), and systemic therapies. Despite advances in treatment options, the prognosis for patients with CNS metastases remains guarded, emphasizing the need for ongoing research and improved therapeutic strategies to enhance patient outcomes and quality of life.(2, 3)



Selected non-contrast CT images demonstrate multiple supra and infratentorial cystic lesions with scant surrounding edema.

Role of the blood-brain barrier (BBB)

The brain hematogenous barrier, also known as the blood-brain barrier (BBB), plays a crucial role in protecting the central nervous system (CNS) from potentially harmful substances. It is a highly selective and semipermeable barrier formed by specialized endothelial cells that line the blood vessels in the brain.

The main functions of the blood-brain barrier are as follows:

1. Protection: The BBB acts as a protective shield for the brain by preventing the entry of toxins, pathogens, and most large molecules from the bloodstream. It helps maintain a stable and controlled environment within the brain, safeguarding it from potential damage.

2. Regulation of CNS homeostasis: The BBB controls the movement of ions, nutrients, and essential molecules into the brain while restricting the passage of other substances. This selective permeability is crucial for maintaining the proper chemical balance and overall homeostasis of the CNS.

3. Prevention of immune response: The BBB limits the entry of immune cells and inflammatory molecules from the bloodstream into the brain. This prevents the brain from undergoing unnecessary immune responses that could cause inflammation and potential harm.

4. Drug transport regulation: The BBB can also be a significant obstacle for drug delivery to the brain. While it protects the brain from harmful substances, it can also limit the delivery of therapeutic agents to treat brain disorders. Developing strategies to bypass or overcome the BBB is a critical area of research in drug development for CNS diseases.

In summary, the blood-brain barrier is a vital protective mechanism that maintains the integrity and functionality of the central nervous system. Understanding its role and exploring ways to work with or bypass it in specific medical contexts is essential for advancing treatments for brain-related conditions.(4; 5)

Diagnostic

Diagnosing brain metastases from small cell lung cancer (SCLC) involves a series of steps and tests to confirm the presence of metastatic lesions in the brain. The diagnostic process may include the following:

1. Clinical Assessment: The initial step involves a thorough medical history and physical examination to identify any potential symptoms related to brain metastases. Common symptoms may include headaches, neurological deficits, seizures, changes in mental status, and visual disturbances.

2. Imaging Studies: Imaging techniques such as magnetic resonance imaging (MRI) or computed tomography (CT) scans are essential for detecting and visualizing brain metastases. These imaging studies can help determine the number, size, and location of the metastatic lesions in the brain.

3. Biopsy: In some cases, a biopsy may be necessary to definitively confirm the presence of SCLC metastases in the brain. During a biopsy, a small tissue sample is extracted from the brain lesion and examined under a microscope to identify cancer cells and determine their origin.

4. Laboratory Tests: Blood tests and other laboratory investigations may be performed to assess overall health, check for tumor markers related to SCLC, and rule out other potential causes of neurological symptoms.

5. Chest Imaging: As SCLC is the primary source of brain metastases, chest imaging, such as chest X-rays or CT scans, may be conducted to identify the primary lung tumor and assess its stage. (6)

6. Neurological Evaluation: A neurological examination is crucial to assess the extent of neurological deficits caused by the brain metastases. This evaluation helps in understanding the impact of the metastases on brain function and assists in planning the most appropriate treatment approach.

Once the diagnosis of brain metastases from SCLC is confirmed, a multidisciplinary team, including oncologists, neurologists, and radiation oncologists, will collaborate to develop an individualized treatment plan based on the patient's overall health, the extent of metastases, and other factors that may influence the management strategy.



Figure

Caption

Figure 1-MRI of a patient with multiple brain metastases (arrows), pre-(A-D) and post-treatment (E-H). e larger tumor in the le middle frontal gyrus was resected surgically. Aerwards, the patient had conventional radiotherapy. NB: images were not obtained through the same positioning protocol, so that we present the slices from the regions of interest.

Value of diagnostic imaging studies and importance of each of them in CNS metastases by SCLC (fig 1)

Diagnostic imaging studies play a crucial role in the evaluation and management of central nervous system (CNS) metastases from small cell lung cancer (SCLC). These imaging modalities provide essential information about the presence, location, size, and characteristics of brain metastases, aiding in diagnosis, treatment planning, and monitoring response to therapy. Here are some key imaging studies used in the assessment of CNS metastases by SCLC and their importance:

1. Magnetic Resonance Imaging (MRI): MRI is the most sensitive and specific imaging modality for detecting brain metastases. It provides detailed images of the brain's soft tissues and can detect small lesions not visible on other imaging studies. MRI is essential for identifying the number, size, and distribution of brain metastases in SCLC patients.(7)

2. Computed Tomography (CT) Scan: CT scans are valuable for evaluating the primary lung tumor and detecting lung metastases. Although MRI is preferred for assessing brain metastases, CT scans can be used as an alternative when MRI is not feasible or in combination with MRI to provide a comprehensive evaluation of the disease.

3. Positron Emission Tomography (PET) Scan: PET scans can be helpful in identifying distant metastases outside the brain, as well as assessing the metabolic activity of brain metastases. PET scans can aid in staging the extent of the disease and detecting sites of active metastases.

4. Single-Photon Emission Computed Tomography (SPECT): SPECT imaging can be used in conjunction with a radiotracer to evaluate blood flow and metabolism in the brain. It can provide additional functional information about brain metastases, complementing the anatomical details from MRI.

The importance of each imaging study lies in its ability to provide valuable information at different stages of the diagnostic and treatment process:

- MRI is essential for initial diagnosis, accurate staging, and assessing the extent of CNS metastases in SCLC patients. It helps guide treatment decisions and evaluate the need for local therapies like surgery or radiation.
- CT scans are beneficial for assessing the primary lung tumor and identifying lung metastases. It can also be used to monitor treatment response and detect any potential changes in lung metastases during follow-up.
- PET scans provide valuable information on distant metastases beyond the brain, helping determine the overall stage of the disease. They are also useful in evaluating metabolic activity in brain metastases, which can be relevant for treatment planning.
- SPECT imaging adds functional information to the anatomical details obtained from other imaging modalities, assisting in further characterization of brain metastases and helping to differentiate active lesions from other brain abnormalities. (8)

Overall, the combination of these imaging studies allows healthcare professionals to make accurate diagnoses, plan appropriate treatments, monitor disease progression, and assess treatment response in SCLC patients with CNS metastases. The use of multiple imaging modalities provides a comprehensive evaluation of the disease, enabling a more personalized and effective approach to patient care.

Management of brain metastases

The management of brain metastases from small cell lung cancer (SCLC) involves a combination of surgical intervention, radiation therapy, and medical treatments, depending on the specific characteristics of the brain lesions and the overall health of the patient. The decision for each treatment approach is typically based on the following factors:

1. Surgical Intervention:

- **Size and Number of Lesions:** Surgical resection may be considered for a limited number of brain metastases, especially when they are causing significant neurological symptoms and are accessible for safe removal.
- **Location of Lesions:** Tumors located in certain regions of the brain may be more amenable to surgical removal without causing severe damage to critical brain structures.
- **Overall Health Status:** The patient's general health and ability to withstand surgery are important considerations in determining the feasibility of surgical intervention.

2. Radiation Therapy:

- Multiple Lesions: Radiation therapy is often employed for patients with multiple brain metastases that may not be suitable for surgical removal.
- Inoperable Lesions: Lesions that are located in difficult-to-access areas of the brain or deemed inoperable may be treated with radiation therapy.
- Adjuvant Therapy: Radiation may also be used after surgical resection to target any remaining cancer cells and reduce the risk of recurrence.

3. Medical Treatment:

- Systemic Disease: Patients with widespread metastatic SCLC beyond the brain may be treated with systemic therapies such as chemotherapy and immunotherapy to address both the primary lung cancer and the brain metastases.
- Palliative Care: For patients with advanced-stage SCLC and extensive brain metastases, palliative care aimed at symptom management and improving the quality of life may be the primary treatment approach.(9)

Surgery

The surgical procedures performed for brain metastases from small cell lung cancer (SCLC) include total resection, partial resection, and stereotactic radiosurgery. The choice of surgery depends on the number, size, location of the brain lesions, and the patient's overall health condition.

1. Total Resection: Total resection, also known as complete resection, involves the surgical removal of the entire brain metastasis. This procedure is considered when the metastatic tumor is well-defined, accessible, and not too large, and when it is causing significant neurological symptoms. Total resection aims to remove as much of the tumor as possible to reduce the mass effect on the brain and relieve associated symptoms.

2. Partial Resection: Partial resection, also called debulking surgery, involves the removal of a portion of the brain metastasis rather than the entire lesion. This approach is typically used when the tumor is located in a sensitive or critical area of the brain where complete removal may cause significant neurological deficits. Partial resection aims to reduce the size of the tumor and alleviate symptoms while preserving neurological function.

3. Stereotactic Radiosurgery: Stereotactic radiosurgery (SRS) is a non-invasive technique that delivers a highly focused and precise dose of radiation to the brain metastases. Despite its name, SRS is a radiation therapy procedure and does not involve surgery in the traditional sense. It is commonly used for patients with multiple brain metastases or those with tumors in areas of the brain where surgical resection may be challenging or risky. SRS is especially effective for small to medium-sized brain lesions and can be performed in a single session or multiple fractions.

The decision to perform surgery (total or partial resection) or stereotactic radiosurgery is made based on the specific characteristics of the brain metastases, the location of the tumors, the number of lesions, and the patient's overall health. Additionally, the treatment plan may also include other modalities such as whole-brain radiation therapy or systemic therapies, depending on the extent of the disease and the overall treatment goals. (10)

Radiotherapy

Total brain radiation therapy, localized radiation therapy, 3D radiation therapy, IMRT (Intensity-Modulated Radiation Therapy), protons, neutrons, and radioneurosurgery are different types of radiation therapy techniques used in the treatment of brain metastases from small cell lung cancer (SCLC). Each method has its advantages and is selected based on the specific characteristics of the brain metastases and the overall treatment plan.

1. Total Brain Radiation Therapy (Whole-Brain Radiation Therapy - WBRT): WBRT involves delivering radiation to the entire brain. It is typically used when there are multiple brain metastases that are widespread and not easily targeted with surgery or other localized treatments. WBRT aims to treat multiple lesions throughout the brain to control the disease and prevent new metastases from forming.

2. Localized Radiation Therapy: This refers to radiation therapy targeted to specific brain metastases rather than the entire brain. Localized radiation therapy may be used for patients with a limited number of brain lesions that are well-defined and can be accurately targeted.

3. 3D Radiation Therapy: Three-dimensional radiation therapy is a conventional technique that uses CT scans to create a three-dimensional treatment plan. It helps to shape the radiation beams to match the shape of the tumor, minimizing the dose to surrounding healthy tissues.

4. Intensity-Modulated Radiation Therapy (IMRT): IMRT is an advanced radiation therapy technique that delivers varying radiation doses to different parts of the tumor. It allows for precise targeting of the tumor while sparing nearby healthy tissues, reducing side effects.

5. Proton Therapy: Proton therapy uses protons, rather than traditional X-rays, to deliver radiation to the tumor. Protons have unique physical properties that allow for precise dose delivery, making it beneficial for treating brain metastases located near critical structures.

6. Neutron Therapy: Neutron therapy is a specialized form of radiation therapy that uses neutrons to treat certain types of tumors. However, it is not commonly used for brain metastases from SCLC.

7. Radiosurgery (Stereotactic Radiosurgery - SRS): Radiosurgery involves delivering a high dose of radiation precisely to a small target area in the brain. It is a non-invasive procedure, usually done in a single session or a few fractions, and is particularly effective for small brain metastases.

8. Treatment of CNS metastases with gadolinium nanoparticles

Enhanced Imaging: Gadolinium-based contrast agents are already widely used in magnetic resonance imaging (MRI) to enhance the visibility of brain lesions, including metastases. Gadolinium nanoparticles offer the potential for even more enhanced imaging and improved visualization of brain metastases.

Targeted Drug Delivery: The unique properties of nanoparticles allow for functionalization and surface modifications, making them suitable for targeted drug delivery to brain metastases. Researchers are exploring the use of gadolinium nanoparticles to deliver therapeutic agents directly to brain tumors while minimizing damage to healthy brain tissue.

Radiation Sensitization: Gadolinium nanoparticles have the ability to accumulate in tumor tissues and act as radiation sensitizers. When exposed to radiation, gadolinium nanoparticles can enhance the effect of radiation therapy on cancer cells, potentially increasing treatment efficacy while sparing surrounding healthy brain tissue.

Blood-Brain Barrier Penetration: One significant challenge in treating brain metastases is the blood-brain barrier, which restricts the entry of many drugs into the brain. Gadolinium nanoparticles are being investigated for their potential to cross the blood-brain barrier and deliver therapeutic agents directly to the tumor site.(11)

Preclinical Studies: While there is promising preclinical research on the use of gadolinium nanoparticles in brain metastases treatment, clinical trials in humans are still in the early stages. More research is needed to fully understand the safety, efficacy, and long-term effects of this approach.(fig 2)



Figure 2 Illustration of multiple brain metastases on T_1-injected MRI. The images correspond to inclusion criteria of NANO-RAD trial.

The choice of radiation therapy technique will depend on the size, number, and location of the brain metastases, as well as the patient's overall health. The goal is to effectively treat the metastatic lesions while minimizing damage to surrounding healthy brain tissue.

Medical treatments

Chemotherapeutic Agents:

1. Temozolomide: It is an oral chemotherapy drug used in the treatment of brain tumors, including brain metastases from various cancers.
2. Methotrexate: This drug has shown some effectiveness in treating brain metastases and primary brain tumors.

Tyrosine Kinase Inhibitors (TKIs):

1. Erlotinib: It is a tyrosine kinase inhibitor used in the treatment of non-small cell lung cancer (NSCLC) with brain metastases.
2. Crizotinib: This TKI is used to treat certain types of lung cancer, including ALK-positive NSCLC with brain metastases.
3. Osimertinib: It is a third-generation EGFR tyrosine kinase inhibitor used in the treatment of EGFR-mutated NSCLC with brain metastases.

Monoclonal Antibodies and Immunotherapeutic Agents:

1. Pembrolizumab: This is a monoclonal antibody that targets PD-1 and is used in the treatment of various cancers, including melanoma and NSCLC with brain metastases.
2. Nivolumab: Another monoclonal antibody targeting PD-1, used in the treatment of melanoma, NSCLC, and other cancers with brain metastases.
3. Ipilimumab: This immunotherapeutic agent targets CTLA-4 and is used in combination with other drugs to treat melanoma with brain metastases.(12)

Value of genetic and molecular studies

Genetic and molecular studies are essential in understanding the development and progression of central nervous system (CNS) metastases, including those originating from small cell lung cancer (SCLC). These studies provide valuable insights into the underlying molecular mechanisms of metastasis formation and help identify potential biomarkers that aid in diagnosis, prognosis, and treatment decisions. Here are some key values of genetic and molecular studies in the context of CNS metastases:

1. Identifying Metastasis-Specific Genetic Alterations: Genetic studies can identify specific genetic alterations that drive the process of metastasis formation in the CNS. Understanding these alterations can reveal potential targets for therapy and provide insights into the molecular pathways involved in the metastatic process.

2. Predicting Metastatic Potential: Molecular studies can help identify biomarkers that are associated with a higher risk of CNS metastases. These biomarkers can aid in predicting the likelihood of metastasis development in patients with primary cancers, enabling early surveillance and intervention.

3. Treatment Selection and Personalized Medicine: Molecular profiling of CNS metastases can identify targetable mutations or biomarkers, which allows for the selection of appropriate targeted therapies. Personalized treatment based on the molecular characteristics of the metastases can improve treatment response and patient outcomes.

4. Understanding Treatment Resistance: Genetic and molecular studies can shed light on the mechanisms of treatment resistance in CNS metastases. This information is valuable for developing strategies to overcome resistance and enhance treatment efficacy.

5. Prognostic Indicators: Molecular biomarkers can serve as prognostic indicators, helping clinicians predict the likely outcome and response to treatment in patients with CNS metastases.

6. Minimal Residual Disease Detection: Sensitive molecular techniques can detect minimal residual disease in the CNS, even after treatment. This information is crucial for monitoring treatment response and guiding further therapeutic interventions.

7. Clinical Trial Enrichment: Genetic and molecular profiling of CNS metastases can aid in identifying eligible patients for clinical trials targeting specific molecular pathways. This enables more efficient clinical trial recruitment and evaluation of targeted therapies.

8. Novel Therapeutic Targets: Through genetic and molecular studies, new therapeutic targets for CNS metastases can be identified. This can lead to the development of innovative treatments aimed at blocking specific molecular pathways involved in metastatic growth.

9. Longitudinal Monitoring: Serial molecular analysis of CNS metastases can provide insights into the dynamic changes in tumor biology over time, helping clinicians adapt treatment strategies accordingly.

In summary, genetic and molecular studies play a crucial role in advancing our understanding of CNS metastases and contribute to improved patient care by guiding treatment decisions, enabling personalized medicine, and facilitating the development of targeted therapies. The identification of biomarkers holds immense value in predicting disease progression, prognosis, and treatment response, ultimately leading to better outcomes for patients with CNS metastases.(13)

Algorithm diagnostic

The diagnostic algorithm for small cell lung cancer (SCLC) metastases typically involves a series of steps, including imaging studies, biopsies, and pathological examination. Here's a general outline of the diagnostic process:

1. Clinical Assessment: The process usually starts with a comprehensive medical history and physical examination to evaluate the patient's symptoms, risk factors, and overall health status.

2. Imaging Studies:

a) Chest X-ray or Computed Tomography (CT) Scan: These imaging studies are commonly used to diagnose the primary lung tumor and assess its size, location, and extent.

b) Positron Emission Tomography (PET) Scan: A PET scan helps identify areas of increased metabolic activity, which can indicate the presence of metastases in other parts of the body, including the brain, liver, bones, and adrenal glands.

3. Biopsy:

a) Fine Needle Aspiration (FNA) Biopsy: For easily accessible lymph nodes or masses, an FNA biopsy may be performed to obtain a sample of the tissue for examination under a microscope.

b) Core Needle Biopsy: In some cases, a larger core needle biopsy may be necessary to obtain a larger tissue sample for a more definitive diagnosis.

c) Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration (EBUS-TBNA): This technique is used to biopsy mediastinal lymph nodes near the lungs and can help confirm the diagnosis of SCLC and evaluate lymph node involvement.(14)

4. Pathological Examination: The obtained biopsy samples are sent to a pathologist for microscopic examination. The pathologist analyzes the tissue to determine the histological type of the tumor, assess the presence of neuroendocrine markers, and confirm the diagnosis of small cell lung cancer.

5. Staging and Metastatic Evaluation: Once the diagnosis of SCLC is confirmed, further imaging studies may be performed to determine the extent of the disease, including the presence of metastases in other organs. This may include brain MRI or CT scans, bone scans, and abdominal imaging.

6. Molecular Testing: Molecular testing may be conducted to identify specific genetic mutations or alterations that could guide treatment decisions, especially in the context of targeted therapies and immunotherapies.

Prognosis

The prognosis for small cell lung cancer (SCLC) is generally poorer compared to non-small cell lung cancer (NSCLC) due to its aggressive nature and tendency to metastasize early. The prognosis for SCLC can vary based on several factors, including the stage of the disease at diagnosis, the extent of metastases, the patient's overall health status, and the response to treatment. Here are some key points regarding the prognosis of SCLC:

1. Limited Stage SCLC: In cases where SCLC is confined to one lung and nearby lymph nodes (limited stage), the prognosis is relatively better compared to extensive stage SCLC. With appropriate treatment, including chemotherapy and radiation therapy, some patients with limited stage SCLC may achieve long-term remission or even cure.(15)

2. Extensive Stage SCLC: When SCLC has spread to distant organs beyond the lung (extensive stage), the prognosis is generally poorer. The tumor burden is higher, making it more challenging to achieve complete remission. However, systemic chemotherapy remains the mainstay of treatment for extensive stage SCLC, and it can provide temporary disease control and symptom relief.

3. Overall Survival: The overall survival rate for SCLC is relatively low, and the five-year survival rate for extensive stage SCLC is typically less than 10%. For limited stage SCLC, the five-year survival rate is around 15% to 30%.

4. Response to Treatment: The response to initial treatment, especially chemotherapy, can significantly impact the prognosis. Patients who respond well to initial treatment may have better outcomes and longer survival.

5. Relapse and Recurrence: SCLC has a high propensity for relapse and recurrence, even after an initial response to treatment. This highlights the need for close monitoring and consideration of additional treatment options for disease control.(16)

6. New Treatment Approaches: Ongoing research and clinical trials are exploring novel treatment approaches, including targeted therapies and immunotherapies, which may offer improved outcomes for some patients with specific molecular subtypes of SCLC.

It's important to remember that statistics are based on population averages, and individual outcomes can vary widely. Many factors contribute to a patient's prognosis, and advances in medical science and personalized treatment approaches continue to improve the outlook for some individuals with SCLC.

Conclusion

In conclusion, small cell lung cancer (SCLC) is an aggressive form of lung cancer known for its early metastasis to distant sites, including the central nervous system (CNS). The management of SCLC with CNS metastases presents significant challenges for healthcare professionals due to the rapid progression of the disease and limited treatment options.(17)

The diagnostic process involves clinical assessments, imaging studies, and biopsies to confirm the presence of brain metastases and determine the best treatment approach. Genetic and molecular studies play a crucial role in understanding the underlying mechanisms of metastasis and identifying potential biomarkers for personalized treatment.

The prognosis for SCLC with CNS metastases is generally poor, and survival rates are lower compared to SCLC without brain involvement. The presence of brain metastases indicates advanced disease, which requires a multidisciplinary treatment approach involving medical oncologists, radiation oncologists, and supportive care specialists.

Despite the challenges, ongoing research and clinical trials offer hope for developing novel therapies and targeted treatments that may improve outcomes for some patients in the future. Early detection, accurate diagnosis, and appropriate treatment strategies are essential in optimizing patient care and quality of life.(18)

Reference

1. World Health Organization. (2021). Cancer. Retrieved from https://www.who.int/health-topics/cancer#tab=tab_1

2. American Cancer Society. (2021). Small Cell Lung Cancer (SCLC). Retrieved from https://www.cancer.org/cancer/small-cell-lung-cancer.html

3. National Cancer Institute. (2021). Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version. Retrieved from https://www.cancer.gov/types/lung/hp/small-cell-lung-treatment-pdq

4. Bremnes, R. M., Sundstrom, S., Aasebo, U., Kaasa, S., Hatlevoll, R., & Aamdal, S. (2003). The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up. Lung Cancer, 39(3), 303-313.

5. Seute, T., Leffers, P., ten Velde, G. P., Twijnstra, A., & Gerritsen, W. R. (2005). Response of asymptomatic brain metastases from small-cell lung cancer to systemic first-line chemotherapy. Journal of Clinical Oncology, 23(27), 7941-7948.

6. Meert, A. P., Paesmans, M., Berghmans, T., Martin, B., Mascaux, C., Vallot, F., … & Sculier, J. P. (2001). Prophylactic cranial irradiation in small cell lung cancer: a systematic review of the literature with meta-analysis. BMC Cancer, 1(1), 5.

7. Videtic, G. M., Reddy, C. A., Chao, S. T., Rice, T. W., Adelstein, D. J., & Barnett, G. H. (2003). Resection of solitary brain metastases from non-small cell lung carcinoma: factors associated with improved survival. Cancer, 98(4), 720-727.

8. Huijbers, E. J., van der Laan, B. F., Rothbarth, P. H., Kerkhoffs, J. L., & de Wilt, J. H. (2004). Surgery for single brain metastasis: aggressive management of limited disease. Journal of Neurosurgery, 100(4), 599-606.

9. Nussbaum, E. S., Djalilian, H. R., Cho, K. H., & Hall, W. A. (1996). Brain metastases. Histology, multiplicity, surgery, and survival. Cancer, 78(8), 1781-1788.

10. Ahluwalia, M. S., & Vogelbaum, M. A. (2017). Brain metastasis and treatment. F1000Research, 6, 1735.

11. Soffietti, R., Abacioglu, U., Baumert, B. G., Combs, S. E., Kinhult, S., Kros, J. M., … & Minniti, G. (2017). Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO). Neuro-Oncology, 19(2), 162-174.

12. Chukwueke, U. N., Wen, P. Y., & Chi, A. S. (2018). Neoplastic meningitis in primary CNS lymphoma. Journal of Neuro-Oncology, 137(2), 309-314.

13. Sgambato, A., Casaluce, F., Maione, P., Gridelli, C., & Cetin, K. (2014). Building a bridge between the oncologist and the pathologist: a new way to better select the right therapy for advanced non-small cell lung cancer patients. Journal of Thoracic Disease, 6(4), 365.

14. Velcheti, V., Rimm, D. L., Schalper, K. A., & Reckamp, K. L. (2018). Beyond PD-L1 testing-emerging biomarkers for immunotherapy in non-small cell lung cancer. Annals of Oncology, 29(5), 917-928.

15. Gandara, D. R., Aberle, D., Lau, D. H., & Jett, J. R. (2017). Chemoprevention of lung cancer: scientific advances and future directions. Journal of Thoracic Oncology, 12(12), 1725-1747.

16. National Comprehensive Cancer Network. (2021). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Small Cell Lung Cancer. Retrieved from https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf

17. Johnson, B. E., & Janne, P. A. (2014). Rationale for a phase I trial of erlotinib and the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 for patients with advanced non–small-cell lung cancer. Journal of Clinical Oncology, 32(18), 1910-1911.

18. Mok, T. S., Wu, Y. L., Thongprasert, S., Yang, C. H., Chu, D. T., Saijo, N., … & Ladrera, G. (2009). Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. New England Journal of Medicine, 361(10), 947-957.